News Release
2018
-
May 30, 2018
Kissei Announces Negative Topline Results from the additional phase III Clinical Trial evaluating "KPS-0373 (Development Code)" for the Treatment of Spinocerebellar Ataxia
-
April 23, 2018
Kissei Announces New President and COO
-
January 17, 2018
JR-131, a Long-Acting Erythropoiesis-Stimulating Agent, Demonstrates Equivalence in Phase III Study
